Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Aumolertinib mesylate by Jiangsu Hansoh Pharmaceutical Group for Non-Small Cell Lung Cancer: Likelihood of Approval
Aumolertinib mesylate is under clinical development by Jiangsu Hansoh Pharmaceutical Group and currently in Phase III for Non-Small Cell Lung...
Data Insights
Aumolertinib mesylate by Jiangsu Hansoh Pharmaceutical Group for Lung Adenocarcinoma: Likelihood of Approval
Aumolertinib mesylate is under clinical development by Jiangsu Hansoh Pharmaceutical Group and currently in Phase I for Lung Adenocarcinoma. According...